Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Income from Continuing Operations rose 21007.2% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 67156.96%. This contributed to the annual value of -$18.5 million for FY2024, which is 19863.15% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $26.6 million for Q3 2025, which was up 21007.2% from $8.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Income from Continuing Operations high stood at $26.6 million for Q3 2025, and its period low was -$24.2 million during Q3 2024.
  • In the last 5 years, Ani Pharmaceuticals' Income from Continuing Operations had a median value of -$2.3 million in 2024 and averaged -$2.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 1837272.73% in 2022, then skyrocketed by 113521.03% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$24.1 million in 2021, then soared by 82.35% to -$4.3 million in 2022, then soared by 127.12% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then soared by 358.86% to $26.6 million in 2025.
  • Its Income from Continuing Operations was $26.6 million in Q3 2025, compared to $8.5 million in Q2 2025 and $15.7 million in Q1 2025.